Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the phase II trial evaluating the efficacy of autologous tumor infiltrating lymphocytes LN-145 (LN-145) in combination with pembrolizumab for treating patients with advanced transitional cell bladder cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:50.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit specific descriptions based on factors like general health or prior treatments. This change provides more context and examples of what eligibility criteria entail.
    Difference
    33%
    Check dated 2024-05-22T20:29:04.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:25:07.000Z thumbnail image

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.